---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-003985"
form_type: "8-K"
ticker: "APTOF"
cik: "0000882361"
company_name: "Aptose Biosciences Inc."
filed_at: "2025-06-20T23:59:59+00:00"
generated_at: "2026-05-19T02:18:27.335599+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aptose enters $8.5M loan agreement with Hanmi for tuspetinib AML development

## Summary
- Loan agreement with Hanmi for up to US$8.5M uncommitted facility to fund continued clinical development of tuspetinib.
- Loan is a related-party transaction; Aptose relies on 'financial hardship' exemption from formal valuation and minority shareholder approval.
- Tuspetinib is an oral agent targeting SYK, FLT3, KIT, JAK1/2, RSK2; ongoing TUSCANY Phase 1/2 trial in newly diagnosed AML with azacitidine and venetoclax.
- Early data from first two dose cohorts showed safety, CRs, and MRD negativity across diverse mutations.

## SEC filing metadata
- accession: 0001171843-25-003985
- form_type: 8-K
- ticker: APTOF
- cik: 0000882361
- company_name: Aptose Biosciences Inc.
- filed_at: 2025-06-20T23:59:59+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882361/000117184325003985/0001171843-25-003985-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882361/000117184325003985/f8k_062025.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-003985
- JSON: https://secwatch.observer/filing/0001171843-25-003985.json
- Plain text: https://secwatch.observer/filing/0001171843-25-003985.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.